Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against iRobot Corporation due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by September 5, 2025 [3][5]. Group 1: Allegations Against iRobot - The complaint alleges that iRobot and its executives made false and misleading statements regarding the effectiveness of their Restructuring Plan following the termination of the Amazon Acquisition [5]. - It is claimed that iRobot overstated its ability to operate profitably as a standalone company, raising substantial doubt about its ability to continue as a going concern [5]. - The company's public statements were deemed materially false and misleading at all relevant times [5]. Group 2: Financial Performance - iRobot reported a loss of $2.06 per share on revenue of $172 million for Q4 and full year 2024, marking a 44% year-over-year decline [6]. - The company expressed uncertainty regarding the success of new product launches due to various factors, including consumer demand and macroeconomic conditions, indicating substantial doubt about its financial viability for at least 12 months [6]. Group 3: Market Reaction - Following the release of the financial results, iRobot's stock price fell by $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Capricor Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its lead drug candidate, deramiocel, and its regulatory status with the FDA [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Capricor between October 9, 2024, and July 10, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Capricor, with a deadline of September 15, 2025, for investors to seek the role of lead plaintiff [3][8]. - The complaint alleges that Capricor and its executives made false and misleading statements regarding the drug deramiocel and its FDA approval process [5]. Group 2: Regulatory Issues and Stock Performance - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying its Biologics License Application (BLA) due to insufficient evidence of effectiveness and the need for additional clinical data [6]. - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, indicating a significant market reaction to the news [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Petco (WOOF) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Petco between January 14, 2021 and June 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder ri ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In iRobot To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in iRobot between January 29, 2024 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 16, 2025 (GLOBE NEW ...

Core Viewpoint - A securities class action lawsuit has been filed against XPLR Infrastructure, LP, alleging misleading statements and omissions regarding the company's financial condition and business model during the class period from September 27, 2023, to January 27, 2025 [1][3]. Company Overview - XPLR Infrastructure, LP, formerly known as Nextera Energy Partners, LP, focuses on acquiring, owning, and managing contracted clean energy projects in the United States, including wind and solar power projects and a natural gas pipeline [2]. Allegations in the Class Action - The lawsuit claims that during the class period, the defendants made misleading statements about XPLR's operations as a yieldco, which is a business model focused on delivering cash distributions to investors [3]. - Specific allegations include: - XPLR was struggling to maintain its yieldco operations [3]. - Defendants entered financing arrangements to temporarily alleviate operational issues while downplaying associated risks [3]. - The company could not resolve these financings before maturity without risking significant unitholder dilution [3]. - Defendants planned to halt cash distributions to redirect funds to resolve financing issues [3]. - The yieldco business model and distribution growth rate were deemed unsustainable [3]. - Public statements made by the defendants were materially false and misleading [3]. Market Reaction - On January 28, 2025, XPLR announced it would suspend cash distributions to common unitholders and abandon its yieldco model, leading to a significant drop in the stock price from $15.80 to $10.49 per unit, a decline of nearly 35% [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against iRobot Corporation for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by September 5, 2025 [3][5]. Group 1: Allegations Against iRobot - The complaint alleges that iRobot and its executives made false and misleading statements regarding the effectiveness of the Restructuring Plan following the termination of the Amazon Acquisition [5]. - It is claimed that iRobot overstated its ability to operate profitably as a standalone company, raising substantial doubt about its ability to continue as a going concern [5]. - The company's public statements were deemed materially false and misleading at all relevant times [5]. Group 2: Financial Performance - iRobot reported a loss of $2.06 per share on revenue of $172 million for Q4 and full year 2024, marking a 44% year-over-year decline [6]. - The company expressed uncertainty regarding the success of new product launches due to various factors, including consumer demand and macroeconomic conditions, indicating substantial doubt about its financial viability for at least 12 months [6]. Group 3: Market Reaction - Following the announcement of its financial results, iRobot's stock price fell by $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to significant losses suffered by investors following misleading statements regarding the safety of its clinical trial for RP-A501 [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who incurred losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations Against Rocket Pharmaceuticals - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. - It was revealed that Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which misled investors into purchasing securities at inflated prices [4]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event, including death, which was not disclosed to investors prior to the incident [5]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].

Core Viewpoint - A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged misleading statements and failure to disclose critical information during the Class Period from April 29, 2025, to June 23, 2025 [1][2]. Company Summary - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, which included the sale of Novo Nordisk's FDA-approved Wegovy® on its platform [2]. - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, jeopardizing patient safety [5]. Legal Allegations - The lawsuit alleges that Hims & Hers made false and/or misleading statements and failed to disclose the risks associated with its collaboration with Novo Nordisk [2][5]. - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers due to these deceptive practices, leading to a significant drop in Hims & Hers' stock price by $18.26 per share, a decline of over 34%, closing at $45.00 per share [2]. Important Dates - The lead plaintiff motion deadline for investors is August 25, 2025 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses [3][5][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - The firm reminds investors of the August 11, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against Rocket Pharmaceuticals [3]. - The complaint alleges that Rocket Pharmaceuticals provided positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [5]. Group 2: Clinical Trial Issues - Rocket Pharmaceuticals faced a clinical hold from the FDA on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event (SAE), which ultimately resulted in death [6]. - The company amended the trial protocol to introduce a new immunomodulatory agent without disclosing this critical update to investors, which is a key point of contention in the lawsuit [5][6]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to alleged violations of federal securities laws, encouraging affected investors to seek legal counsel before the August 11, 2025 deadline for lead plaintiff applications in a federal class action lawsuit [3][5]. Group 1: Allegations Against PepGen - The complaint alleges that PepGen and its executives made false or misleading statements regarding the effectiveness and safety of PGN-EDO51, and failed to disclose deficiencies in the CONNECT2 study, leading to overstated clinical and commercial prospects [5]. - The FDA issued a clinical hold notice for the CONNECT2 study, indicating concerns about patient risks and deficiencies in the study [8]. Group 2: Stock Price Reactions - Following the announcement of disappointing clinical data from the CONNECT1 study, PepGen's stock price fell by $5.55, or 32.69%, closing at $11.43 on July 31, 2024 [7]. - After the FDA's clinical hold notice on December 16, 2024, PepGen's stock dropped by $0.17, or 3.63%, to close at $4.51 [9]. - On January 30, 2025, PepGen's stock fell by $0.40, or 21.74%, to close at $1.44 after updates on safety concerns in the CONNECT1 study [10]. - The stock price further declined by $0.53, or 18.86%, to close at $2.28 on March 4, 2025, following the announcement to pause the CONNECT2 study [11]. - On May 28, 2025, PepGen announced the discontinuation of its DMD programs after PGN-EDO51 failed to achieve target dystrophin levels [12]. Group 3: Legal and Investor Actions - Investors who suffered losses exceeding $50,000 in PepGen between March 7, 2024, and March 3, 2025, are encouraged to contact Faruqi & Faruqi for legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding PepGen's conduct [14].